52w high/low | ₹4579.85 / ₹2958.2 |
P/E ratio | 201.25 |
Dividend | 0.36 |
ROE | 18.95 |
ROCE | 23.93 |
Face value | 2 |
Book value | ₹271.74Cr |
Market capital | ₹16,487.63Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
AstraZeneca Pharma India (APIL) is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Alimentary & Metabolism, Cardio Vascular, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25. 75% of the Company's issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. AstraZeneca Pharmaceuticals AB Sweden. AstraZeneca Pharma India Limited (the Company') is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom.